Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03801525
Title Study to Assess the Efficacy and Safety of Ublituximab Plus Umbralisib in Combination With Venetoclax in Subjects With CLL (ULTRA-V)
Acronym ULTRA-V
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.